Peter Karachunski
Expertise in
55
conditions

Dr. Peter Karachunski

Neuromusculoskeletal Medicine | Neurology | Pediatric Neurology
2512 South 7th Street, Floor 3, 
Minneapolis, MN 
Accepting New Patients
Offers Telehealth
Expertise in
55
conditions
2512 South 7th Street, Floor 3, 
Minneapolis, MN 

Overview

Peter Karachunski is a Neuromusculoskeletal Medicine specialist and a Neurologist practicing medicine in Minneapolis, Minnesota.

Dr. Karachunski is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Duchenne Muscular Dystrophy, Paramyotonia Congenita, Myotonic Dystrophy, and Myotonic Dystrophy Type 2.

Dr. Karachunski is board certified in Neuromuscular Medicine: American Board Of Psychiatry And Neurology, 2008. He is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 5 clinical trials. Dr. Karachunski is currently accepting new patients.

Residency

University of Minnesota-Neurology, Child Neurology - 2005

Specialties

Neuromusculoskeletal Medicine
Neurology
Pediatric Neurology

Licenses

Child & Adolescent Psychiatry in MN

Board Certifications

Neuromuscular Medicine: American Board Of Psychiatry And Neurology, 2008

Fellowships

University of Minnesota-Neurology, Neurophysiology - 2006

Hospital Affiliations

M Health Fairview University Of Mn Medical Center

Languages Spoken

English
Russian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PreferredOne
  • HMO
  • OTHER COMMERCIAL
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford Health
  • HMO
  • PPO
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

M Health Fairview Discovery Pediatric Specialty Clinic
2512 South 7th Street, Floor 3, Minneapolis, MN 55454
Other Locations
M Health Fairview Infusion Services UMMC
606 24th Avenue South, Suite 215, Minneapolis, MN 55454
M Health Fairview EMG Clinic Minneapolis
909 Fulton Street Southeast, Floor 3, Minneapolis, MN 55455

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension
Enrollment Status: Completed
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

29 Total Publications

Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.
Journal: Journal of comparative effectiveness research
Published: August 22, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Peter Kang
Neuromusculoskeletal Medicine | Neurology | Pediatric Neurology
Expertise in
12
conditions
Dr. Peter Kang
Neuromusculoskeletal Medicine | Neurology | Pediatric Neurology
Referral may be required

M Health Fairview Discovery Pediatric Specialty Clinic

2512 South 7th Street, Floor 3, 
Minneapolis, MN 
 (0.6 miles away)
612-365-6777
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Peter Kang is a Neuromusculoskeletal Medicine specialist and a Neurologist practicing medicine in Minneapolis, Minnesota. Dr. Kang is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Cockayne Syndrome, Limb-Girdle Muscular Dystrophy, Cockayne Syndrome Type 1, Cockayne Syndrome Type 2, and Thymectomy. Dr. Kang is board certified in Neuromuscular Medicine: American Board Of Psychiatry And Neurology, 2008, Clinical Neurophysiology: American Board Of Psychiatry And Neurology, 2003, and Pediatrics: American Board Of Pediatrics, 2001. Dr. Kang is currently accepting new patients.

Expertise in
8
conditions
Dr. Jeffrey Allen
Neurology | Neuromusculoskeletal Medicine
Expertise in
8
conditions
Dr. Jeffrey Allen
Neurology | Neuromusculoskeletal Medicine
Referral may be required

M Health Fairview EMG Clinic Minneapolis

909 Fulton Street Southeast, Floor 3, 
Minneapolis, MN 
 (0.4 miles away)
612-626-6680
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Allen is a Neurologist and a Neuromusculoskeletal Medicine provider practicing medicine in Minneapolis, Minnesota. Dr. Allen is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Polyradiculoneuritis, Multifocal Motor Neuropathy, and Guillain-Barre Syndrome. Dr. Allen is board certified in Neuromuscular Medicine: American Board Of Psychiatry And Neurology, 2011 and Neurology: American Board Of Psychiatry And Neurology, 2008. Dr. Allen is currently accepting new patients.

Expertise in
37
conditions
Dr. Georgios Manousakis
Neurology | Neuromusculoskeletal Medicine
Expertise in
37
conditions
Dr. Georgios Manousakis
Neurology | Neuromusculoskeletal Medicine
Referral may be required

M Health Fairview EMG Clinic Minneapolis

909 Fulton Street Southeast, Floor 3, 
Minneapolis, MN 
 (0.4 miles away)
612-626-6680
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Georgios Manousakis is a Neurologist and a Neuromusculoskeletal Medicine provider practicing medicine in Minneapolis, Minnesota. Dr. Manousakis is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Paramyotonia Congenita, Myotonic Dystrophy Type 2, and Myotonic Dystrophy. Dr. Manousakis is board certified in Neuromuscular Medicine: American Board Of Psychiatry And Neurology, 2011 and Neurology: American Board Of Psychiatry And Neurology, 2010. Dr. Manousakis is currently accepting new patients.

Frequently Asked Questions about Dr. Peter Karachunski

How do I make an appointment with Dr. Peter Karachunski?

You can book an appointment with Dr. Peter Karachunski by calling their office at 612-365-6777. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peter Karachunski a top-rated expert for Duchenne Muscular Dystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peter Karachunski is classified as an Distinguished expert for Duchenne Muscular Dystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peter Karachunski specialize in?

While Dr. Peter Karachunski is a Neuromusculoskeletal Medicine, they have specific expertise in Duchenne Muscular Dystrophy, Paramyotonia Congenita, and Myotonic Dystrophy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neuromusculoskeletal Medicine.

Does Dr. Peter Karachunski participate in research or clinical trials?

Yes. Dr. Peter Karachunski has published 29 articles and abstracts on conditions like Duchenne Muscular Dystrophy. You can view a list of Dr. Peter Karachunski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Peter Karachunski accept my insurance?

Dr. Peter Karachunski accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 612-365-6777 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karachunski's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile